Retargeting FX-binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop

References

1. Alba R., Bradshaw A. C., Parker A. L., Bhella D., Waddington S. N., Nicklin S. A., van Rooijen N., Custers J., Goudsmit J. et al. 2009; Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114:965–971 [View Article][PubMed]
   [Google Scholar]
2. Alba R., Bradshaw A. C., Coughlan L., Denby L., McDonald R. A., Waddington S. N., Buckley S. M., Greig J. A., Parker A. L. et al. 2010; Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116:2656–2664 [View Article][PubMed]
   [Google Scholar]
3. Atoda H., Ishikawa M., Mizuno H., Morita T. 1998; Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein. Biochemistry 37:17361–17370 [View Article][PubMed]
   [Google Scholar]
4. Bergelson J. M., Cunningham J. A., Droguett G., Kurt-Jones E. A., Krithivas A., Hong J. S., Horwitz M. S., Crowell R. L., Finberg R. W. 1997; Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320–1323 [View Article][PubMed]
   [Google Scholar]
5. Cannistra S. A., Ottensmeier C., Niloff J., Orta B., DiCarlo J. 1995; Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol 58:216–225 [View Article][PubMed]
   [Google Scholar]
6. Dmitriev I., Krasnykh V., Miller C. R., Wang M., Kashentseva E., Mikheeva G., Belousova N., Curiel D. T. 1998; An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72:9706–9713[PubMed]
   [Google Scholar]
7. George S. J., Wan S., Hu J., MacDonald R., Johnson J. L., Baker A. H. 2011; Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation 124:S135–S142 [View Article][PubMed]
   [Google Scholar]
8. Guo L., Zhang F., Cai Y., Liu T. 2009; Expression profiling of integrins in lung cancer cells. Pathol Res Pract 205:847–853 [View Article][PubMed]
   [Google Scholar]
9. Hofherr S. E., Shashkova E. V., Weaver E. A., Khare R., Barry M. A. 2008; Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 16:1276–1282 [View Article][PubMed]
   [Google Scholar]
10. Huard J., Lochmüller H., Acsadi G., Jani A., Massie B., Karpati G. 1995; The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 2:107–115[PubMed]
    [Google Scholar]
11. Kalyuzhniy O., Di Paolo N. C., Silvestry M., Hofherr S. E., Barry M. A., Stewart P. L., Shayakhmetov D. M. 2008; Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A 105:5483–5488 [View Article][PubMed]
    [Google Scholar]
12. Krasnykh V., Dmitriev I., Mikheeva G., Miller C. R., Belousova N., Curiel D. T. 1998; Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 72:1844–1852[PubMed]
    [Google Scholar]
13. Ma J., Duffy M. R., Deng L., Dakin R. S., Uil T., Custers J., Kelly S. M., McVey J. H., Nicklin S. A. et al. 2015; Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. PLoS Pathog 11:e1004673 [View Article][PubMed]
    [Google Scholar]
14. Mizuno H., Fujimoto Z., Atoda H., Morita T. 2001; Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X. Proc Natl Acad Sci U S A 98:7230–7234 [View Article][PubMed]
    [Google Scholar]
15. Parker A. L., Waddington S. N., Buckley S. M., Custers J., Havenga M. J., van Rooijen N., Goudsmit J., McVey J. H., Nicklin S. A. et al. 2009; Effect of neutralizing sera on factor X-mediated adenovirus serotype 5 gene transfer. J Virol 83:479–483 [View Article][PubMed]
    [Google Scholar]
16. Parker A. L., White K. M., Lavery C. A., Custers J., Waddington S. N., Baker A. H. 2013; Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Ther 20:1158–1164 [View Article][PubMed]
    [Google Scholar]
17. Pasqualini R., Koivunen E., Ruoslahti E. 1997; Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15:542–546 [View Article][PubMed]
    [Google Scholar]
18. Reynolds P., Dmitriev I., Curiel D. 1999; Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther 6:1336–1339 [View Article][PubMed]
    [Google Scholar]
19. Southgate K., Newby A. C. 1990; Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 82:113–123 [View Article][PubMed]
    [Google Scholar]
20. Soyombo A. A., Angelini G. D., Bryan A. J., Jasani B., Newby A. C. 1990; Intimal proliferation in an organ culture of human saphenous vein. Am J Pathol 137:1401–1410[PubMed]
    [Google Scholar]
21. Tomko R. P., Xu R., Philipson L. 1997; HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 94:3352–3356 [View Article][PubMed]
    [Google Scholar]
22. Vigne E., Mahfouz I., Dedieu J. F., Brie A., Perricaudet M., Yeh P. 1999; RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 73:5156–5161[PubMed]
    [Google Scholar]
23. Waddington S. N., McVey J. H., Bhella D., Parker A. L., Barker K., Atoda H., Pink R., Buckley S. M., Greig J. A. et al. 2008; Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132:397–409 [View Article][PubMed]
    [Google Scholar]
24. Xu Z., Qiu Q., Tian J., Smith J. S., Conenello G. M., Morita T., Byrnes A. P. 2013; Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 19:452–457 [View Article][PubMed]
    [Google Scholar]
25. Zitzmann S., Ehemann V., Schwab M. 2002; Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor- endothelial cells in vivo. Cancer Res 62:5139–5143[PubMed]
    [Google Scholar]